Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Central Nervous System

What are the options available for the treatmen...

Retinal vein occlusion (RVO) is the second most common vision-threatening disorder that happens due to retinal vascular disease. If left untreated, RVO can result in vision impairment and a signifi...

Nov 27, 2020

recent-pharma-news-and-updates-for-santhera-merck-novartis-scribe
Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma

Designing a universal flu vaccine by focusing on the immune system  A universal flu vaccine that can foster protection to people against any influenza strain is considered a goal in flu research as it could spare scientists from the often erroneous process of predicting the circulating strains each year and...

Find More
pharma-news-updates-for-biomarin-gilead-alzheon
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Find More
recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g
Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...

Find More

More Views & Analysis

latest pharma news
MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic’s IMU-838 promising results

MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...

Find More

recent-Pharma-news-and-happenings
Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...

Find More

Frontotemporal-dementia-market
Addressing The Scattered Harbingers of Frontotemporal Dementia

The Frontotemporal dementia market is expected to increase with a CAGR of 21.41% for 7MM during the study period. However, pharma companies such as TauRx Therapeutics, Axon Neuroscience SE, Prevail Therapeutics, Avid Radiopharmaceuticals, and Alector are actively working to buildup the Frontotemporal dementia pipel...

Find More

pharma-news
Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin

Amylyx Pharmaceuticals grabs USD 30 Million  Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS). AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease....

Find More

Pharma-news
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M

Regeneron recognizes new combos to boost I-O drug Libtayo's cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance...

Find More

marijuana-to-treat-Alzheimer's
Can Alzheimer’s be cured with Marijuana?

Alzheimer's is a progressive brain disorder that results in the degeneration of brain cells. It affects the thinking, reasoning, memory, and problem-solving skills of the person. Apart from cognitive function, it also influences mood, personality, behavior, and social skills. In the advanced stages, the patients ar...

Find More

Today, Artificial Intelligence has been used effectively in data processing, drug discovery, aiding .....

Find More

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More

Cocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....

Find More

Over the years, the Oncology domain has experienced the entry of several treatment approaches. Thera.....

Find More

Tinnitus is a condition where a person experiences different kinds of noises in one or both ears. It.....

Find More

Gene Therapy has shown tremendous growth in the past few years. The use of AAV (adeno-associated vir.....

Find More